Mass General Brigham’s Medicare Advantage plan is removing Dana-Farber Cancer Institute from its network, forcing hundreds of patients to seek alternative care by October 1, with one 88-year-old cancer survivor calling the move collateral damage
in a healthcare realignment.
Eldon Clingan, an 88-year-old prostate cancer survivor, has been receiving treatment at Dana-Farber Cancer Institute for over two decades. His care will now be jeopardized after the Mass General Brigham Health Plan, which operates separately from the hospital system, announced its decision to remove Dana-Farber from its Medicare Advantage network. Starting October 1, patients like Clingan will face difficult choices about their medical coverage, with the 90-day transition period offering temporary relief but no long-term solution.
Patient’s Struggle and the 90-Day Transition
Clingan, who has relied on the same oncologist for 23 years, expressed deep concern over the changes. I have had excellent care from my Dana-Farber doctor for 23 years and I want to stay with her,
he said, adding, I want to stay with the medication that she has prescribed. I don't know for certain how I can do that.
The Mass General Brigham Health Plan cited the challenging environment impacting Medicare Advantage plans nationwide
as the reason for the network change. However, Clingan sees the move as part of a broader conflict between healthcare providers, stating, I feel like I am collateral damage in this war.
Under the 90-day transition period, affected patients can continue their current care until the new year. After the first of the new year, they will need a new insurance plan to maintain coverage at Dana-Farber. This includes patients undergoing ongoing treatments such as radiation or chemotherapy, but the uncertainty remains for those who rely on specific medications or long-term care relationships. It adds to the anxiety and worry, which you know, at age 88 with cancer, you really do not need that kind of stress in your life,
Clingan said.
The Split Between MGB and Dana-Farber
The decision comes after Dana-Farber decided to end its long-term partnership with the Mass General Brigham hospital system in 2028. MGB maintains that the insurance network change is unrelated to the ongoing clinical separation and realignment among cancer providers in Boston.
However, Clingan and other patients view the move as interconnected, with the insurance provider’s decision exacerbating the disruption caused by the clinical split. Sick people should not have to suffer this kind of stress in addition to the stress of cancer, which for most of us, one way or the other, is going to be fatal,
Clingan added.
Dana-Farber’s decision to part ways with MGB in 2028 marked a significant shift in the local healthcare landscape. The cancer institute, renowned for its research and treatment, had maintained a collaborative relationship with the hospital system for years. The separation has led to a reevaluation of how care is structured, with insurance providers like MGB adjusting their networks in response to the evolving healthcare ecosystem.
Impact on Patients and Coverage Options
The Mass General Brigham Medicare Advantage plan serves approximately 20,500 members, though only a fraction receive cancer care at Dana-Farber at any given time. Despite the relatively small number of affected patients, the emotional and logistical burden is significant. For Clingan, the prospect of switching doctors or insurance plans is daunting. Are they going to cover my medication, for example? This is very expensive medication,
he asked, highlighting the financial and medical uncertainties.
Patients impacted by the change have limited options. They can either seek care at other facilities within the Medicare Advantage network or switch to a different insurance plan that includes Dana-Farber. However, transitioning to a new plan may involve additional costs and administrative hurdles. The 90-day window provides some flexibility, but the long-term implications remain unclear. I have had excellent care from my Dana-Farber doctor for 23 years and I want to stay with her,
Clingan reiterated, underscoring the personal stakes involved.
Broader Implications for Medicare Advantage Plans
The situation at Dana-Farber highlights the challenges faced by Medicare Advantage plans as they navigate shifting healthcare partnerships and financial pressures. The MGB Health Plan’s decision reflects broader trends in the industry, where insurers must balance cost management with maintaining access to specialized care. For patients, the experience underscores the vulnerability of relying on insurance networks that can change without notice.
Sick people should not have to suffer this kind of stress in addition to the stress of cancer,
Clingan said, a sentiment shared by many in the medical community. The case also raises questions about the stability of Medicare Advantage plans and the need for greater transparency in network changes.
What Comes Next for Affected Patients?
As the October 1 deadline approaches, patients like Clingan are left in limbo. Some may opt to switch insurance plans, while others may seek care at alternative facilities. The long-term impact on patient outcomes remains uncertain, particularly for those who rely on specific treatments or medications. I feel like I am collateral damage in this war,
Clingan said, echoing the frustration of many who feel caught between institutional decisions and their personal health needs.
For now, the focus remains on navigating the immediate challenges. Clingan’s story serves as a poignant reminder of the human cost behind healthcare policy changes. As the healthcare landscape continues to evolve, the experiences of patients like him will shape the conversation around access, affordability, and the importance of stable, patient-centered care.
